Rafael Andres Vicens-Rodriguez MD, Presenter: Nothing to Disclose

Raghunandan Vikram MBBS, FRCR, Abstract Co-Author: Nothing to Disclose

Pheroze Tamboli MD, Abstract Co-Author: Nothing to Disclose

Naveen Garg MD, Abstract Co-Author: Consultant, Document Storage Systems, Inc CEO, Garglet LLC

Srinivasa R. Prasad MD, Abstract Co-Author: Nothing to Disclose

Christopher G. Wood MD, Abstract Co-Author: Consultant, Pfizer Inc Investigator, Pfizer Inc Speaker, Pfizer Inc Consultant, Argos Therapeutics, Inc Investigator, Argos Therapeutics, Inc Investigator, GlaxoSmithKline plc

1. After viewing this exhibit, the learner will know the background, pathology and multimodality imaging features of this new type of renal cell carcinoma.   2. Additionally, the learner will distinguish the imaging differences between tubulocystic renal cell carcinoma and other types of RCC.    

-Background   - Genetics and Pathology.   - Multimodality imaging features (US, CT, MRI). --> Retrospective cohort (N=10).  - Imaging differences from other types of RCC.   -Conclusion.  

http://abstract.rsna.org/uploads/2014/14002382/14002382_5v6f.pdf

Vicens-Rodriguez, R, Vikram, R, Tamboli, P, Garg, N, Prasad, S, Wood, C, Tubulocystic Renal Cell Carcinoma: A New Recognized Epithelial Tumor.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14002382.html